Drawing for LEXOGEN THE RNA EXPERTS

USPTO serial 79313035

LEXOGEN THE RNA EXPERTS

Reviewed by CopyMark Law Group

Reg. 6848794Status 700Registered
Filing date
Status date
Registration date
Sep 20, 2022
Examiner
BAIRD, MICHAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LEXOGEN THE RNA EXPERTS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael J. Leonard

Michael J. Leonard Fox Rothschild LLP997 Lenox Drive, Bldg. 3Lawrenceville, NJ 08648-2311UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical and biochemical preparations for industrial and scientific purposes; chemical preparations for industrial biotechnical purposes; chemical preparations for use in the development of biotechnological products for industrial and scientific purposes; chemical reagents and preparations for scientific purposes; chemical substances for analysis in laboratories other than for medical or veterinary purposes and for use in test kits for laboratory or research use; diagnostic reagents for in-vitro use in clinical chemistry; diagnostic preparations, except for medical or veterinary purposes; enzymes, in particular for use in kits for industrial and scientific purposes; all aforementioned goods for industrial and scientific purposes; reagents for scientific purposesACTIVE—
009Software, in particular downloadable software for data analysisACTIVE—
010Blood testing equipment; genetic testing apparatus for medical purposesACTIVE—
042Computer system design services in the field of genetic research, development and diagnostics; Development of software, in particular software for data analysis servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jan 31, 2023FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 5, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 5, 2023FIMPFINAL DISPOSITION PROCESSED—
Dec 28, 2022GPNXNOTIFICATION PROCESSED BY IB—
Dec 20, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Sep 20, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Sep 20, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 5, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 5, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 29, 2022OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 29, 2022OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jun 15, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 31, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 31, 2022XAECEXAMINER'S AMENDMENT ENTERED—
May 31, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 31, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
May 31, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
May 30, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 30, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 30, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 19, 2021RFNTREFUSAL PROCESSED BY IB—
Nov 30, 2021RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 30, 2021RFRRREFUSAL PROCESSED BY MPU—
Nov 26, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 20, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 19, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 19, 2021DOCKASSIGNED TO EXAMINER—
Nov 19, 2021DOCKASSIGNED TO EXAMINER—
Nov 19, 2021DOCKASSIGNED TO EXAMINER—
Nov 18, 2021RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Oct 22, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 21, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 29, 2021DOCKASSIGNED TO EXAMINER—
Jun 16, 2021MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 12, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 10, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance